5 minute read
Jun. 8, 2023

A Second-Generation AR Bifunctional Degrader for Drug-Resistant Prostate Cancer

ARV-766

oral AR-degrading PROTAC Ph. II for adv. prostate cancer from CRBN-based E3 recruiter + AR ligand AACR, April 2023 Arvinas, New Haven, CT

twitterlinkedinprintemail

MOTY Nominees

Molecule of the Year